By Isabel Demetz (Reuters) -Swiss contract drugmaker Lonza plans to simplify its structure and exit its capsules and health ...

Swiss contract drugmaker Lonza plans to exit its capsules and health ingredients (CHI) business, it said on Thursday, after ...

With a new CEO at the helm, Swiss CDMO Lonza is looking to revivify its business by doubling down on contract manufacturing ...

Lonza forecasts 2025 CER sales growth of nearly 20%, supported by organic growth and acquisitions, with CORE EBITDA margins nearing 30%. The streamlined organizational model, operational by Q2 2025, ...

Lonza Group AG / Key word (s): Strategic Company Decision Lonza Investor Update 2024 Outlines Strategy, New Organizational Structure and Guidance 12-Dec-2024 / 06:25 CET/CEST Release of an ad hoc ...

Investing.com -- Lonza’s shares rose over 6% on Thursday following the company’s announcement of plans to divest its Capsules ...

Swiss healthcare manufacturing organization Lonza saw its shares rise 7% to 559.40 francs in early trading, as it announced ...

Lonza Group Ltd (GB:0QNO) has released an update.Pick the best stocks and maximize your portfolio:Discover top-rated stocks from highly ranked ...

Find insight on Lonza, the Max Healthcare Institute and Fortis Healthcare in the latest Market Talks covering Health Care.

Recent developments in the health sector include a dosing pause in Keros Therapeutics' drug trial, Corcept Therapeutics' ALS ...

Synaffix B.V., a Lonza company (SIX: LONN) focused on commercializing its clinical-stage platform technology for the development of antibody-drug conjugates (ADCs) with best-in-class therapeutic index ...